Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis

Peter Messiaen¹, Annemarie M. J. Wensing², Axel Fun², Monique Nijhuis², Nele Brusselaers¹, Linos Vandekerckhove¹*

¹General Internal Medicine and Infectious Diseases, Ghent University Hospital, Ghent, Belgium, ²Virology, Department of Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens. The purpose of this study was to review the evidence for integrase inhibitor use in clinical settings.

Methods: MEDLINE and Web-of-Science were screened from April 2006 until November 2012, as were hand-searched scientific meeting proceedings. Multiple reviewers independently screened 1323 citations in duplicate to identify randomized controlled trials, nonrandomized controlled trials and cohort studies on integrase inhibitor use in clinical practice. Independent, duplicate data extraction and quality assessment were conducted.

Results: 48 unique studies were included on the use of integrase inhibitors in antiretroviral therapy-naive patients and treatment-experienced patients with either virological failure or switching to integrase inhibitors while virologically suppressed. On the selected studies with comparable outcome measures and indication (n = 16), a meta-analysis was performed based on modified intention-to-treat (mITT), on-treatment (OT) and as-treated (AT) virological outcome data. In therapy-naive patients, favorable odds ratios (OR) for integrase inhibitor-based regimens were observed, (mITT OR 0.71, 95% CI 0.59–0.86). However, integrase inhibitors combined with protease inhibitors only did not result in a significant better virological outcome. Evidence further supported integrase inhibitor use following virological failure (mITT OR 0.27; 95% CI 0.11–0.66), but switching to integrase inhibitors from a high genetic barrier drug during successful treatment was not supported (mITT OR 1.43; 95% CI 0.89–2.31). Integrase inhibitor-based regimens result in similar immunological responses compared to other regimens. A low genetic barrier to drug-resistance development was observed for raltegravir and elvitegravir, but not for dolutegravir.

Conclusion: In first-line therapy, integrase inhibitors are superior to other regimens. Integrase inhibitor use after virological failure is supported as well by the meta-analysis. Careful use is however warranted when replacing a high genetic barrier drug in treatment-experienced patients switching successful treatment.

Citation: Messiaen P, Wensing AMJ, Fun A, Nijhuis M, Brusselaers N, et al. (2013) Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis. PLoS ONE 8(1): e52562. doi:10.1371/journal.pone.0052562

Editor: Luis Menéndez-Arias, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Spain

Received June 19, 2012; Accepted November 19, 2012; Published January 9, 2013

Copyright: © 2013 Messiaen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have read the journal’s policy and have the following conflicts: PM, AF and NB do not have conflict of interest nor relevant financial interests. AMWJ has served as a consultant to BMS, Gilead, Viiv Health Care, has received grants from MSD, Pfizer, Viiv Healthcare, and has received travel accommodations, and meeting expenses from European Medical Agency, GSK, Viiv Healthcare, Pfizer, Gilead, Jansen, MSD, and BMS. MN has served as a consultant to MSD, has received grants from MSD, GSK, BMS, Abbott, European Commission and Roche and has received travel accommodation and meeting expenses from Jansen. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: Linos.Vandekerckhove@ugent.be

Introduction

Since the first reports on Acquired Immunodeficiency Syndrome (AIDS), the human immunodeficiency virus (HIV) has caused a devastating pandemic with yearly 2.6 million new infections worldwide [1]. The stable integration of the reverse transcribed viral genome into host chromatin forms an important point-of-no-return during HIV infection. Raltegravir is the first representative of a new class of antiretroviral drugs targeting the strand transfer reaction during this integration process. Strand transfer integrase inhibitors bind in the catalytic core domain of the enzyme and compete for binding with host DNA. Introduction of raltegravir in 2008 appeared almost simultaneously with approval of second generation drugs of existing therapeutic classes as the protease inhibitor (PI) darunavir and the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine. Combined use of these drugs has resulted in high levels of virological suppression in treatment-experienced populations [2,3]. As a result, the treatment goals in highly experienced patients have been redefined towards successful suppression of plasma viral load [4,5]. In addition to high efficacy, the initial use of this first integrase inhibitor (INI) also suggested good tolerability, a favorable safety profile and absence of significant drug-drug interactions. Follow-
HIV Integrase Inhibitors in Clinical Settings

Methods

Data Sources and Searches
We followed a protocol using the methodological approaches outlined in the Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews [6] and applied the PRISMA Guidelines [7]. The systematic literature review aimed at including all published studies from April 2006 until November 2012 reporting on the clinical use of INIs for antiretroviral therapy. We searched MEDLINE and Web-of-Science with the MeSH terms “integrase inhibitor”, “HIV” or “raltegravir” or “elvitegravir” or “dolutegravir”. We systematically hand-searched the meeting proceedings (abstract books, trial registries and reference lists) from key conferences that were held in the same period: the Conference on Retroviruses and Opportunistic Infections, the European Workshop on HIV & Hepatic Treatment Strategies & Antiviral Drug Resistance, the International HIV Drug Resistance Workshop, the International AIDS Conference, the European AIDS Conferences, the International Congress on Drug Therapy in HIV Infection and the Interscience Conference on Antimicrobial Agents and Chemotherapy.

Study Selection
The initial selection was performed by two independent investigators. We included original research papers or abstracts of clinical trials on the use of INIs in HIV-positive patients. We included randomized controlled trials, non-randomized trials, retrospective analysis of these trials, cohort studies or cross-sectional studies. Language restrictions were set on English. We excluded in vitro and animal studies, review articles, studies with experimental drugs currently not evaluated in clinical trials in humans, studies on the prophylactic use of INIs and studies in pediatric patient populations (younger than 16 years). We assessed all titles and abstracts identified by our search and excluded reviews or reports describing obviously different topics other than clinical data related to INI use. Discrepancies were resolved by consensus or by consulting a third reviewer. Of the remaining reports, we read the abstracts and excluded reports if they dealt with non-clinical factors or described only pharmacokinetic and pharmacodynamic data. Case reports and studies with small patient cohorts (<10) were excluded and subsequently full-length articles were retrieved from all published papers. The flow diagram is depicted in Figure 1.

Data Extraction and Quality Assessment
All selected articles or abstract-only reports were carefully read and analyzed. The quality assessment of the studies selected in the systematic review is depicted in Figure 2. We assessed the strength of evidence by using the GRADE [Grading of Recommendations Assessment, Development and Evaluation] approach [8] (Table 2). In this way, a body of evidence is evaluated regarding four major domains: risk of bias, consistency, directness and precision of study outcomes. This results in four strength of evidence grades: high, moderate, low or insufficient.

Data Synthesis
The following data were collected: (a) basic study characteristics: study period, prospective or retrospectively gathered data, number of participating centers; (b) population characteristics: population size, pre-trial antiretroviral treatment, exclusion criteria; (c)

Table 1. Main characteristics of the integrase inhibitors used in clinical practice or in clinical trials in humans.

| Generic Name | FDA/EMA status | Dosing Recommendations | Serum Half-life | Route of Metabolisation | Major Adverse Events |
|--------------|----------------|------------------------|-----------------|-------------------------|----------------------|
| Raltegravir  | FDA/EMA approved for therapy-naive and experienced patients | 400 mg BD - no food restrictions | ~9 hrs | UGT1A1- mediated glucuronidation | nausea and diarrhea - skin rash with fever (rare) - CPK elevation, muscle weakness, rhabdomyolysis - transient elevation of serum transaminase levels - hypersensitivity reactions, hepatitis |
| Elvitegravir | FDA approved for therapy-naive patients as part of single tablet regimen | 150 mg QD, + booster (100 mg ritonavir or cobicistat) - to be taken with meals | ~9.5 hrs if boosted | Predominantly cytochrome P450 (CYP3A4) metabolized, minor pathways via UGT1A1/3 glucuronidation and oxidative metabolism | nausea and diarrhea - headache, insomnia - eGFR decrease when combined with cobicistat (inhibition of tubular secretion of creatinine) |
| Dolutegravir | Phase III studies ongoing | 50 mg QD INI-naive patients, 50 mg BD INI-experienced patients - no food restrictions | ~15 hrs | Predominantly UGT1A1-mediated glucuronidation, cytochrome P450 (CYP3A4) metabolism as minor pathway | nausea and diarrhea - transient low-level increases in serum creatinine - eGFR decrease (inhibition of tubular secretion of creatinine) - hypersensitivity reactions, hepatitis |

FDA (Food and Drug Administration) and EMA (European Medicines Agency) status, dosing recommendations, serum-half-life, main route of metabolism and currently reported major adverse events are indicated.

BD = twice-daily; QD = once-daily.
doi:10.1371/journal.pone.0052562.t001

PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e52562
intervention characteristics: drugs used, drug dosage, duration of treatment and follow-up; (d) outcome parameters: virologic and immunologic response, genotypic data of eventual drug resistance at therapy failure, clinical and laboratory adverse events.

Data Analysis
A random-effects meta-analysis was used to investigate the combination or interaction of this collection of independent studies. This was performed using STATA/MP4 (release 11; StataCorp LP, Texas USA; STATA module ‘mais’) following the Mantel-Haenszel model to obtain weighted odds ratios (OR) and 95% confidence intervals (CI) of virological outcome data [9,10]. An OR of one indicates no difference between both groups; ORs below one indicate benefit of INI versus the control regimen. If the 95% CI of the OR contains the value 1, there is no sufficient evidence for a difference between both treatment groups. For the calculation of these ORs, the virological outcome data were normalized towards time-point (24 or 48 weeks after start of INI). Studies reported virological outcome data based on: TLOVR (time-to-loss-of-virological-response) (n = 2), snapshot approach.
Table 2. Overview of studies in systematic review, grouped according to study-design and indication: regimens, population size, treatment duration and summary of main outcome data and conclusions.

| ART-naive patients: INI in combination with dual NRTI | Regimen | (w) | Summary |
|-----------------------------------------------------|---------|-----|---------|
| STARTMRK [15–19] | RAL 400 mg bd + TDF/FTC vs. EFV + TDF/FTC | 240 | Non-inferiority of raltegravir in reaching VL<50 c/ml (71% vs 61.3% EFV, mITT); Significantly more rapid decline of viral load in early phase with INI; Mean CD4 increase 374 (INI) versus 312 cells/ml (EFV). |
| Protocol 004 [20–22] | RAL 100, 200, 400 or 600 mg bd + TDF/3TC vs. EFV + TDF/3TC | 240 | Similar proportions of VL<50 c/ml (69% vs 63%, mITT) in all dosages (400 mg bd single arm as from w48) - non-inferiority for raltegravir; Similar mean CD4 increase (302 versus 267 cells/ml); Less frequent drug-related clinical adverse events with raltegravir (55%) than efavirenz (76%). |
| SHIELD [24] | RAL 400 mg bd + ABC/3TC | 96 | Proportion of VL<50 c/ml (mITT 77%); Median CD4 increase 304 cells/ml; No drug-related serious adverse events reported |
| GS-236-014 [26] | EVG/COBI single tablet qd + TDF/FTC vs. EFV + TDF/FTC | 48 | Non-inferiority of elvitegravir/cobicistat in suppressing VL<50 c/ml (mITT: 90% vs 83% treatment difference +8.4% (~8.8 to +25.6%). Treatment with EVG/COBI associated with more rapid achievement of undetectable VL than EFV/FTC/TDF (P<0.05 at weeks 2, 4 and 8). Lower rate of drug-related central nervous system and psychiatric adverse events in EVG/COBI group |
| GS-236-0102 [25] | EVG/COBI/FTC/TDF qd vs EFV/TDF/FTC | 48 | Non-inferiority of QUAD (EVG/COBI/TDF/FTC) in suppressing VL<50 c/ml (mITT: 87.6% vs 84.1% treatment difference +3.6% CI -1.6 to +8.8%). Treatment with QUAD associated with higher CD4 increase at 48w (239 cells/μL vs 206 cells/μL, p = 0.009). Similar numbers of patients discontinued treatment because of an adverse event in each group. Nausea was more common in the QUAD group, CNS and psychiatric adverse events more frequent with EVF |
| SPRING-1 [27–29] | DTG 10,25 or 50 mg + TDF/FTC or ABC/3TC vs. EFV + TDF/FTC or ABC/3TC | 48 | Similar response rates (VL<50 c/ml) for all doses of dolutegravir compared to efavirenz (mITT 87% versus 82%); Median CD4 increase in all dolutegravir groups were higher than efavirenz (231 cells per μL vs 174 cells per μL; p=0.076); No serious adverse events related to dolutegravir |
| SINGLE [14] | DTG 50 mg + ABC/3TC vs. EFV/TDF/FTC | 48 | Significant better virological reponse of DTG/ABC/3TC vs. EFV/TDF/FTC (mITT 88% vs 81%); median CD4 increase significantly higher in DTG/ABC/3TC (267 vs 208 cells/μL; p<0.001) No INI or NRTI resistance observed in the DTG-treated group and no serious adverse events. |
| GS-236-0103 [31] | EVG/COBI/FTC/TDF qd vs ATV/r + TDF/FTC | 48 | Non-inferiority of QUAD (EVG/COBI/TDF/FTC) in suppressing VL<50 c/ml (mITT 89.5% vs 86.8%; treatment difference +3.0% CI -1.9 to +7.8%). Similar increase of CD4 count in both groups. Similar numbers of patients discontinued treatment because of an adverse event in each group. More Grade 3 and 4 lab abnormalities in the ATV/r group compared to QUAD. |
| SPRING-2 [30] | DTG 50 mg qd + TDF/FTC or ABC/3TC vs. RAL 400 mg bd + TDF/FTC or ABC/3TC | 48 | Non-inferiority of dolutegravir versus raltegravir in reaching VL<50 c/ml (ITT 88% vs 85%). Similar median CD4 increase (230 CD4 cells/μL). Discontinuation due to serious adverse events 2% in each group. No IN or NRTI resistance upon failure in DTG group versus 1 and 4 pts in the RAL groups. |
| QDMRK [23] | RAL 800 mg bd + TDF/FTC vs. RAL 400 mg bd + TDF/FTC | 48 | mITT: 83% in the once-daily group had virological response compared with 89% in the twice-daily group (difference −5.7%, 95% CI −10.7 to −0.83; p = 0.044); Mean CD4+ increase comparable in both groups; serious adverse events reported in 7% and 10% of resp. once-daily recipients and twice-daily recipients. |
### Table 2. Cont.

| Study | ART-naive patients: INI in combination with PI | ART-experienced patients: virological failure |
|-------|-----------------------------------------------|---------------------------------------------|
|       | INI (n=) | CTRL (n=) | Regimen | [w] | Summary |
| **SPARTAN [13]** | 63 | 31 | RAL 400 mg bd + ATV vs. ATV/r + TDF/FTC | 24 | Through week 24, both arms achieved comparable efficacy rates (ITT 74.6% vs 63.3% VL<50 c/ml) |
| **PROGRESS [32]** | 101 | 105 | RAL 400 mg bd + LPV/r vs. LPV/r + TDF/FTC | 48 | Non-inferiority of the study regimen at reaching VL<40 c/ml at week 48 (ITT 81.2% vs 85.7%; difference =4.5%; 95% CI, −15.1% to 5.9%); Mean CD4 increase was similar between groups. |
| **ACTG A5262 [34]** | 112 | N | RAL 400 mg bd + DRV/r | 48 | DRV/r plus RAL was effective (mITT 73% VL<50 c/ml at week 48) and well tolerated in treatment-naive patients, but those with base-line viral load >100,000 copies/ml had more VF and INI resistance. |
| **RADAR [33]** | 40 | 40 | RAL 400 mg bd + DRV/r vs. DRV/r + TDF/FTC | 24 | mITT VL<50 c/ml at week 24 achieved in 75.0% (RAL treated) versus 82.5%; mean CD4 increase +143 versus 109 cells/ml |
| **Fallon et al [83]** | 15 | 15 | RAL 400 mg bd (naive) + LPV/r vs. RAL 400 mg bd (exp) + LPV/r | 48 | mITT: 80.0% (12/15 treatment-naive) versus 73.3% (11/15 treatment-experienced) had VL<50 c/ml at 48 weeks; mean CD4 change 102 versus 66 cells/ml |
| **BENCHMRK 1 and 2 (2,35)** | 462 | 237 | RAL 400 mg bd + NNRTI + NRTI vs. Placebo + NNRTI + NRTI | 96 | Sustained VL<30 c/ml in the combined studies of 57% (raltegravir) versus 26% (placebo) (mITT 96w); mean CD4 increase 109 versus 45 cells/ml (P<0.001 for each study individually and the combined studies); Frequencies and exposure-adjusted rates of clinical adverse events and laboratory abnormalities similar in both groups. |
| **Protocol 005 [36,37]** | 133 | 45 | RAL 200, 400 or 600 mg bd + optimized BR vs. Placebo + optimized BR | 96 | Raltegravir in all doses superior than placebo in reaching undetectable VL at double-blind phase (till 24 weeks); No dose-dependent differentiation in the safety or antiviral activity of raltegravir; After 96weeks (RAL 400 mg bd >24w all groups) 55% and 48% reached VL<400 c/ml and VL<50 c/ml (mITT); There were few discontinuations of raltegravir (4%) due to adverse events. |
| **ANRS 139 TRIO [3]** | 103 | N | RAL 400 mg bd + ETV + DRV/r | 96 | mITT: 86% VL<50 c/ml at 48w; median CD4 increase 108 cells/ml. Grade 3 or 4 clinical adverse events reported 14.6%, though only 1 patient discontinued the regimen because of an adverse event |
| **Canestri et al [39]** | 20 | N | RAL 400 mg bd + ETV + optimized BR | 24 | mITT: 65% of patients reached VL<40 c/ml and 100% VL<400 c/ml; median CD4 increase >80cells/ ml |
| **Nozza et al [41]** | 28 | N | RAL 400 mg bd + MVC + ETV | 48 | mITT/OT: At week 48, 26/28 patients achieved VL<50 c/ml. The median CD4 increase was 267 cells/µL. No patient discontinued treatment. |
| **Caby et al [42]** | 67 | N | RAL 400 mg bd + BR | 48 | At 48 weeks, 43/67 patients had complete (VL<50 c/ml) and 16/67 incomplete (VL<400 c/ml) suppression, while 8 patients failed (mITT). Upon failure, 6/8 patients harbored RAL resistance. |
| **GS-183-105 [38]** | 205 | 73 | EVG/RIT 20, 50 or 125 mg bd + optimized BR vs. PI/r + optimized BR | 24 | mITT: Elvitegravir 50 mg was noninferior and elvitegravir 125 mg superior compared with the PI/r (based on DAVG24 scores). Efficacy was impacted by activity of background agents. Similar mean CD4 increase across all treatment arms; no relationship between elvitegravir dosage and adverse events. |
| **GS-183-0145 [43]** | 361 | 363 | EVG 150 mg qd + PI/r + NRTI vs. RAL 400 mg bd + PI/r + NRTI | 48 | Elvitegravir non-inferior (59%) compared to raltegravir (58%) in achieving complete virological response (mITT treatment difference =1-1%, 95% CI −6.0 to 8.2); Median CD4 increases and proportion of adverse events attributed to study drugs similar in the two treatment arms. |
| **VIKING I [45,46]** | 27 | N | DTG 50 mg qd + optimized BR | 24 | mITT: 52% and 41% of patients treated till 24weeks achieved VL<400 c/ml and VL< 50 c/ml; Drug related AEs (any grade) were observed in 6 (22%) subjects |
| Table 2. Cont. | INI (n =) | CTRL (n =) | Regimen | (w) | Summary |
|----------------|----------|------------|---------|-----|---------|
| **VIKING II [47]** | 24 | N | DTG 50 mg bd + BR | 11d | After 11 days of functional monotherapy (triple resistant virus including INI), 54% of patients reached VL < 400 c/ml (mITT). No discontinuation due to AE/lab toxicities. 17% treatment emergent grade 3 lab abnormalities. |
| **ART-experienced patients: switch strategy** | | | | | |
| **SWITCHMRK 1 and 2 [48]** | 353 | 354 | RAL 400 mg bd + BR = LPV/r vs. BR | 24 | 84.4% in the raltegravir group versus 90.6% in the lopinavir-ritonavir group (mITT treatment difference -6.2%, -11.2 to -1.3) had VL < 50 c/ml, leading to study stop. Majority of RAL-failures had RAL resistance. Mean CD4 increase was small and did not differ between treatment groups. |
| **SPIRAL [49]** | 139 | 134 | RAL 400 mg bd + BR = PI/r vs. BR | 48 | Non-inferiority of raltegravir (mITT 89.2% versus 86.6% of patients remained free of treatment failure [difference +2.6%; 95% CI =-2.7 to 10.6]; No differences between treatment groups in CD4 increase |
| **EASIER ANRS 138 [50]** | 85 | 85 | RAL 400 mg bd + BR -- T20 vs. BR ++ T20 or RAL (>24w) | 48 | At week 48, 90% of patients in both the immediate and deferred groups had plasma VL < 50 c/ml (mITT); Median CD4 cell counts remained stable during follow-up. |
| **ODIS [55]** | 149 | 73 | RAL 800 mg qd + BR = PI/r vs. RAL 400 mg bd + BR = PI/r | 24 | 6.4% in the oncedaily arm and 2.9% in the twice-daily arm (mITT) experienced virological failure, with significant higher rates in patients with prior nucleoside reverse transcriptase inhibitor resistance (16.2% versus 0.7%; P<0.001); significant increase in CD4 (+32 cells/ml) after switch to RAL. |
| **RASTA [56]** | 21 | 19 | RAL 400 mg bd + TDF/FTV vs. RAL 400 mg bd + ABC/3TC | 24 | One virological failure in TDF/FTC arm at 24 weeks; At 24w, a higher increase in CD4 count was observed in arm B versus arm A (mean +62 vs -9 cells/mm3 respectively, p = 0.04). |
| **Talbot et al [53]** | 28 | N | RAL 400 mg bd + BR -- T20 | 24 | 26/2/7 patients with data at 24 weeks remained with a VL < 50 c/ml; No significant changes, statistically or clinically, were observed in the CD4 counts |
| **CHEER [54]** | 52 | N | RAL 400 mg bd + BR -- T20 | 24 | 49/52 (94.2%, confidence interval: 1.2% to 15.9%) remained with a VL < 50 c/ml at 24 weeks (mITT); Mean CD4 increase of 32 cells/ml was seen after 24 weeks |
| **Harris et al [51]** | 35 | N | RAL 400 mg bd + BR -- T20 | 16 | 34/35 patients have HIV RNA < 50 c/ml at 16 weeks of follow-up (mITT) |
| **Santos et al [52]** | 36 | N | RAL 400 mg bd + BR -- T20 | 48 | All but 1 patient (discontinuation) maintained VL < 50 copies/ml at Weeks 24 and 48 |
| **Reliquet et al [57]** | 20 | N | RAL 400 mg bd + NVP | 48 | At week 48, 19/20 patients (100% undetectable VL at start) achieved VL < 50 c/ml (mITT) |
| **ART-experienced patients: treatment intensification** | | | | | |
| **Hatano et al [63]** | 15 | 15 | RAL 400 mg bd + BR vs. Placebo + BR | 48 | The proportion of subjects with undetectable VL did not differ between the 2 groups (mITT p = 0.42); Raltegravir intensification did not have a significant effect on immune activation or HIV-specific responses in PBMCs or gut-associated lymphoid tissue. |
| **CORAL [59]** | 19 | 54 | RAL 400 mg bd + BR vs. HIBC/placebo + BR | 24 | Compared with placebo, the addition of neither raltegravir nor HIBC to cART for 24 weeks resulted in a significant change in CD4 count (mITT mean difference, 95% confidence interval [CI]: 3.09 cells/ll, 214.27; 20.45, p = .724 and 9.43 cells/ll, 27.81; 26.68, p = .279, respectively) |
| **ACTG A5244 [62]** | 25 | 24 | RAL 400 mg bd + BR vs. placebo + BR | 12 | 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. |
(n = 3) or protocol-defined composite-endpoints (n = 11). In order to reveal differences between virological efficacy and ancillary benefits (e.g. lower toxicity, more convenient formulation), we extracted modified intention-to-treat (mITT) as well as on-treatment (OT) and as-treated (AT) data [11,12]. mITT includes all patients who received at least one dose of study drug and completed the study, missing data are considered as failures, as are non-completers. OT includes only the patients completing the study at the analyzed endpoint. Patient-data were censored in case of toxicity, loss to follow-up, lack of efficacy before the endpoint is reached and other reasons. AT is similar to OT, but includes patients with virological failure before the endpoint is reached. Only controlled studies with virological outcome data comparing RAL versus another compound or placebo were included. If data were not available in the paper, authors were contacted and invited to provide it. We assessed statistical heterogeneity using the I-square statistic that measures the degree of inconsistency across studies; it results in a 0–100% range quantifying the proportion of variation in the effect, which is due to inter-study variation, with lower values indicating more homogenous study results. We predefined heterogeneity (I² ≤ 25% for low, 25% < I² < 50% for moderate, and I² ≥ 50% for high). Funnel plots in different subcategories were constructed to assess bias. A pooled analysis was made of all available data on immunological efficacy, adverse events and emergence of drug resistance when using INIs.
Table 3. Study characteristics of studies included in meta-analysis (n = 16): regimens, population size, timepoint of analysis and virological outcome data are enlisted.

| ART-naive patients | INI (n =) | CTR (n =) | Regimen | Analysis time point (w) |
|--------------------|-----------|-----------|---------|------------------------|
| STARTMRK [16]      | 281       | 282       | RAL 400 mg bd + TDF/FTC vs. EFV + TDF/FTC | 48         |
| Protocol 004 [21]  | 160       | 38        | RAL 100, 200, 400 or 600 mg bd + TDF/3TC vs. EFV + TDF/3TC | 48         |
| GS-236-014 [26]    | 48        | 23        | EVG/CObi single tablet qd= TDF/FTC vs. EFV + TDF/FTC | 48         |
| GS-236-0102 (25)   | 348       | 352       | EVG/CObi/TDF qd vs EFV/TDF/FTC | 48         |
| SPRING-1 [28]      | 155       | 50        | DTG 10,25 or 50 mg + TDF/FTC or ABC/3TC vs. EFV + TDF/FTC or ABC/3TC | 48         |
| SINGLE [14]        | 414       | 419       | DTG 50 mg + ABC/3TC vs. EFV/TDF/FTC | 48         |
| GS-236-0103 [31]   | 353       | 355       | EVG/CObi/TDF qd vs ATV/r + TDF/FTC | 48         |
| SPARTAN [13]       | 63        | 31        | RAL 400 mg bd + ATV vs ATV/r + TDF/FTC | 24         |
| PROGRESS [32]      | 101       | 105       | RAL 400 mg bd + LPV/r vs. LPV/r + TDF/FTC | 24         |
| RADAR [33]         | 40        | 40        | RAL 400 mg bd + DRV/r vs. DRV/r + TDF/FTC | 24         |

| ART-experienced patients with virological failure | |
|--------------------------------------------------|---|
| BENCHMRK 1 and 2 [2]                            | 461 | 237 | RAL 400 mg bd + NNRTI + NRTI vs. Placebo + NNRTI + NRTI | 24 |
| Protocol 005 [36,37]                            | 134 | 45  | RAL 200, 400 or 600 mg bd + optimized BR vs placebo + optimized BR | 24 |
| GS-183-105 [38]                                 | 205 | 73  | EVG/RIT 20, 50 or 125 mg bd + optimized BR vs PI/r + optimized BR | 24 |

| ART-experienced patients switching suppressive therapy | |
|--------------------------------------------------------|---|
| SWITCHMrk 1 and 2 [48]                                 | 353 | 354 | RAL 400 mg bd + BR – LPV/r vs. BR | 24 |
| SPIRAL [49]                                           | 139 | 134 | RAL 400 mg bd + BR – PI/r vs. BR | 32 |
| EASIER ANRS 138 [50]                                  | 85  | 85  | RAL 400 mg bd + BR – T20 vs BR + T20 or RAL (>24w) | 24 |

INI-containing treatment arm is underlined. ART = antiretroviral treatment; INI = integrase inhibitor; CTR = control arm; VL <50 = viral load or HIV RNA <50 copies/ml; RAL = raltegravir; EFV = efavirenz; EVG = elvitegravir; CObi = cobicistat; DTG = dolutegravir; ATV = atazanavir; DRV = darunavir; TDF/FTC = tenofovir/emtricitabine; ABC/3TC = abacavir/lamivudine; LPV = lopinavir; r = ritonavir; [N]NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; BR = background regimen; T20 = enfuvirtide.

doi:10.1371/journal.pone.0052562.t003

Results

Systematic review

The systematic review resulted in 48 eligible studies on the clinical use of integrase inhibitors, of which 15 abstract-only reports (Figure 1). These studies include in total more than 9400 HIV-infected patients. Of these studies, 38 (79%) described interventions regarding raltegravir use. Elvitegravir and dolutegravir were respectively investigated in 5 (10%) studies each. The average study population size was 202 (IQR 28–222), the average study duration 48 weeks (IQR 24–48). All but four of the included studies were prospective, the majority randomized (59%) and multi-centered (59%). Blinding was performed in 48% of the studies, 20 studies were single-arm (Figure 2). Study characteristics of all studies with latest result updates and evidence levels per category can be found in Table 2, the studies and data used in the meta-analysis are listed in Table 3.

Meta-analysis

Subsequently a meta-analysis of virological outcome (number of patients achieving HIV RNA below 50 copies/ml) was performed on the 16 controlled studies that compared an INI-based regimen with placebo or other drug classes for similar indications and in which similar endpoints could be evaluated (same measures and same available time-point results). This resulted in three subcategories (treatment-naïve patients, treatment-experienced patients with virological failure and patients switching successful suppressive therapy) and the exclusion of studies on treatment intensification, due to the absence of comparable endpoints. The results of the meta-analysis are visualized in Forest plots (Figure 3 and Figure S1). Low heterogeneity in the outcome was seen in the treatment-naïve subgroup (mITT, I² 0.0%) and the patients switching successful suppressive therapy group (mITT, I² 23.6%). Higher heterogeneity was seen in the studies for patients experiencing virological failure (mITT, I² 83.7%), which points to a higher inter-study variation on virological outcome (Figure S2).

Clinical outcome in antiretroviral-naïve patients

Based on our pre-defined criteria for meta-analysis, we included ten studies on treatment naïve patients. Overall, INI based regimens showed a better virological outcome, which reached significance in the mITT analysis (OR 0.71, 95% CI 0.59–0.86; Figure 3A and OT analysis (OR 0.63, 95% CI 0.47–0.84; Figure S1A). The meta-analysis using AT data (OR 0.86, 95% CI 0.61–1.22; Figure S1A) showed a similar but non-significant favourable trend for INI-based regimens. For one study, no OT or AT data could be obtained [13], for another study AT data were lacking [14].

Comparison of INI versus NNRTI both in combination with dual NRTI

A sub-analysis of the virological outcome data at 48 weeks comparing INI versus NNRTI showed an OR favoring INIs over efavirenz in the mITT meta-analysis (OR 0.67, 95% CI 0.54–0.84) and OT meta-analysis (OR 0.59, 95% CI 0.43–0.81).

In STARTMrk, raltegravir twice-daily (n = 281) was compared to once-daily efavirenz (n = 282) with a backbone of tenofovir/emtricitabine [15–19]. Raltegravir showed non-inferi-
A

Forest plot of studies with ART-naive patients - mITT

| Study | Weeks | OR (95% CI) | Weight |
|-------|-------|-------------|--------|
| 1.1 INI in combination with dual NRTI versus NRTI | 48 | 0.73 (0.47, 1.15) | 17.24 |
| STARTMRK | 48 | 1.11 (0.39, 3.13) | 3.23 |
| Protocol 004 | 48 | 0.55 (0.13, 2.29) | 1.73 |
| GS-239-014 | 48 | 0.75 (0.49, 1.14) | 19.03 |
| GS-239-0102 | 48 | 0.52 (0.22, 1.27) | 4.43 |
| SPRING-1 | 48 | 0.57 (0.39, 0.84) | 23.89 |
| SINGLE | 48 | 0.67 (0.54, 0.84) | 69.55 |
| Subtotal (I-squared = 0.0%, p = 0.806) | - | 0.77 (0.49, 1.21) | 16.61 |
| 1.2 INI in combination with dual NRTI versus PI | 48 | 0.54 (0.22, 1.35) | 4.14 |
| GS-239-0103 | 48 | 0.92 (0.45, 1.88) | 6.73 |
| Subtotal (I-squared = 9.2%, p = 0.332) | - | 0.88 (0.52, 1.50) | 13.84 |
| 1.3 INI in combination with PI versus dual NRTI | 24 | 1.57 (0.53, 4.65) | 2.97 |
| SPARTAN | 24 | 0.71 (0.59, 0.88) | 100.00 |
| PROGRESS | 24 | 1.77 (0.49, 1.21) | 16.61 |
| RADAR | 24 | 0.71 (0.59, 0.88) | 100.00 |
| Subtotal (I-squared = 0.0%, p = 0.785) | - | 0.77 (0.49, 1.21) | 16.61 |

NOTE: Weights are from random effects analysis

better virological outcome for INI-based regimen

worse virological outcome for INI-based regimen

B

Forest plot of studies with ART-experienced patients in case of virological failure - mITT

| Study | Weeks | OR (95% CI) | Weight |
|-------|-------|-------------|--------|
| 2.1 INI versus placebo both in combination with optimized background | 24 | 0.50 (0.22, 0.42) | 38.97 |
| BENCHMRK 1 and 2 | 24 | 0.68 (0.36, 0.69) | 27.67 |
| Subtotal (I-squared = 85.5%, p = 0.006) | - | 0.68 (0.36, 0.69) | 27.67 |
| 2.2 INI versus PI both in combination with optimized background | 24 | 0.65 (0.33, 1.09) | 33.36 |
| GS-183-105 | 24 | 0.27 (0.11, 0.68) | 100.00 |
| Overall (I-squared = 83.7%, p = 0.002) | - | 0.27 (0.11, 0.68) | 100.00 |

NOTE: Weights are from random effects analysis

DARVIR score

better virological outcome for INI-based regimen

worse virological outcome for INI-based regimen

C

Forest plot of studies with ART-experienced patients switching with suppressed viral load - mITT

| Study | Weeks | OR (95% CI) | Weight |
|-------|-------|-------------|--------|
| 3.1 INI versus PI both in combination with dual NRTI | 24 | 1.88 (1.19, 2.97) | 57.59 |
| SWITCHMRK 1 and 2 | 32 | 0.86 (0.54, 1.38) | 21.45 |
| Subtotal (I-squared = 54.3%, p = 0.139) | - | 1.42 (0.88, 2.37) | 79.37 |
| 3.2 INI versus T20 both with background regimen | 24 | 1.14 (0.44, 2.97) | 20.63 |
| EASIER ANRS 158 | 24 | 1.43 (0.86, 2.31) | 100.00 |
| Overall (I-squared = 23.6%, p = 0.270) | - | 1.43 (0.86, 2.31) | 100.00 |

NOTE: Weights are from random effects analysis

better virological outcome for INI-based regimen

worse virological outcome for INI-based regimen
ority based on the primary virological endpoint from 48 up to 240 weeks (mITT 48 week treatment difference +4.2%, 95% CI 1.9 to 10.3). Moreover viral decline in the early treatment phase was significantly more rapid in the raltegravir arm. In the rare cases resistance was observed, multiple raltegravir resistance associated mutations were detected (Table S1). In Protocol 004, an initial dose-ranging trial comparing raltegravir (n = 160) to efavirenz with tenofovir/lamivudine (n = 38) as backbone, similar virological and immunological results at 48 weeks (mITT) were observed as in STARTMRK at all doses [20–22]. Few but high-level raltegravir resistance was detected.

Amongst the studies with raltegravir in antiretroviral-naive patients which could not be incorporated in the meta-analysis, QDMRK, comparing once-daily raltegravir (800 mg qd) versus twice-daily raltegravir (400 mg bd), yields important additional information. Despite high levels of suppression in both arms, the once-daily arm was inferior compared to the twice-daily arm (mITT) [23]. This higher virological failure rate was observed mainly in patients starting with high baseline viral load and low CD4 through levels at 24 hours. Resistance was rare but more frequent in the once-daily arm. Also not included was the uncontrolled SHIELD study, which evaluated raltegravir in combination with abacavir/lamivudine (n = 35) and reported a high proportion (77%) of patients reaching undetectable viral load at 96 weeks in mITT analysis [24].

In the GS-236-0102 phase 3 study, elvitegravir combined with the booster cobicistat and a backbone of emtricitabine and tenofovir (QUAD) (n = 348) was compared to efavirenz with the same backbone (n = 352) both formulated as single tablet regimens (STR). The QUAD STR showed non-inferiority based on the primary virological endpoints up to 48 weeks (mITT 48 weeks treatment difference: +3.6% CI -1.6 to +8.8%) [25]. As has been reported for studies with raltegravir, a more rapid initial HIV RNA decline with elvitegravir was observed compared to the efavirenz arm. In both arms, similar small proportions of patients developed drug resistance upon therapy failure (both arms n = 8). In case of INI resistance in the QUAD failure group, NRTI resistance was observed as well, while in the comparator arm the detection of resistance was mainly limited to NNRtIs.

In the smaller GS-236-014 phase 2 study, the elvitegravir containing QUAD STR (n = 48) was also compared to an efavirenz containing STR (n = 23) with the same NRTI-backbone [26]. Although more patients in the elvitegravir arm achieved an undetectable viral load after one year of follow-up (mITT +8.4%, 95% CI –8.8 to +25.6), this was not statistically significant. Treatment failures were rare and no drug resistance could be assessed. The INI based regimen was well tolerated and fewer adverse events were reported.

In SPRING-1, a phase II dose-ranging randomized trial, a third INI dolutegravir was evaluated. Three different once-daily dosing arms (n = 51 each) were tested against efavirenz (n = 50) with either abacavir/lamivudine or tenofovir/emtricitabine [27–29]. Interim results at 48 weeks of follow-up provide favorable virological outcome in all dolutegravir arms driven by better tolerability (mITT, % of patients with HIV RNA <50 copies/ml: 87% dolutegravir arm versus 82% efavirenz arm). In the few cases of treatment failure, the interim analysis at 48 weeks from SPRING-1 did not detect mutations associated with dolutegravir resistance.

The follow-up study SPRING-2 compared dolutegravir 50 mg (n = 413) versus raltegravir 400 mg (n = 414), both combined with dual NRTI backbone [30]. This study was not included in the meta-analysis since it compared two INIs. After 48 weeks, similar proportions of patients on both INI regimens achieved undetectable viremia (ITT, % of patients with HIV RNA <50 copies/ml: 95% versus 85%). In the dolutegravir treated group, no resistance was detected upon failure, while in the raltegravir treated patients one INI and four NRTI mutations were observed.

The SINGLE trial compared two STR in therapy-naive patients: dolutegravir combined with abacavir/lamivudine (n = 414) versus efavirenz combined with tenofovir/emtricitabine (n = 419) [14]. A significantly better virological outcome after 48 weeks for the dolutegravir-treated group was reported (mITT treatment difference +7.4%; 95% CI +2.5 to +12.3; p = 0.003), while also a significant better immunological response (CD4 increase 267 cells/µl versus 204 cells/µl). The dolutegravir STR was very well tolerated and no INI or NRTI resistance was detected.

**Comparison of INI versus PI both in combination with dual NRTI.** In the GS-236-0103 study, the elvitegravir containing QUAD STR (n = 353) was evaluated against ritonavir boosted atazanavir combined with emtricitabine/tenofovir (n = 353) [31]. At 48 weeks, the QUAD regimen showed non-inferiority based on suppression below 50 copies/ml (mITT treatment difference +3.0% CI –1.9 to +7.8%). In five cases of the QUAD group, resistance was observed versus none in the boosted PI treated group. Of those five, primary INI resistance was seen in four and NRTI resistance in three patients.

**Comparison of INI versus dual NRTI both in combination with PI.** In the search for simplification strategies, INI based NRTI-sparing regimens have been explored. A sub-analysis of this simplification approach indicated a favorable but non-significant OR in favor of INI compared to 2 NRTI when both are combined with a PI at 24 weeks using mITT data (OR 0.88, 95% CI 0.52–1.50) (Figure 3A).

In the randomized open-label SPARTAN trial, raltegravir with unboosted atazanavir (n = 63) was compared to ritonavir boosted atazanavir plus tenofovir/emtricitabine (n = 31) [13]. Through week 24, both arms achieved comparable efficacy rates (ITT % of patients with HIV RNA <50 copies/ml: 74.6% versus 63.3%). The higher rates of hyperbilirubinemia with twice-daily atazanavir and an increased development of raltegravir resistance in the INI-treated group, prompted early termination of the study. Upon virological failure, four out of five evaluable raltegravir treated patients developed high-level raltegravir resistance. In the PROGRESS trial, raltegravir with ritonavir boosted lopinavir (n = 101) was compared to ritonavir boosted lopinavir (n = 105) with tenofovir/emtricitabine [32] and reported non-inferiority of the study regimen at reaching HIV RNA <40 copies/ml at week 48 (ITT, 81.2% versus 85.7%; difference –4.5%; 95% CI,

Figure 3. Forest Plot of mITT meta-analyses. Panel A: Forest plot showing the meta-analysis of mITT data extracted from studies with therapy-naive patients. Besides an overall analysis, three sub-analyses for three different comparisons are depicted. The black line indicates OR = 1, signifying no benefit of the INI arm compared to the non-INI arm. The dotted line shows the odds ratio of all included studies. The individual odds ratios as well as the proportionate weight in the overall analysis are shown in the right column. Panel B: Forest plot showing the meta-analysis of mITT data extracted from studies with ART-experienced patients in case of virological failure. Panel C: Forest plot showing the meta-analysis of mITT data extracted from studies with ART-experienced patients switching with suppressed viral load. mITT = modified intention-to-treat; ART = antiretroviral treatment; INI = integrase inhibitor; NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; T20 = enfuvirtide; OR = odds ratio.

doi:10.1371/journal.pone.0052562.g003
reaching successful virological outcomes after 24 weeks (mITT while in the 125 mg arm (n = 73) elvitegravir was superior at compared with ritonavir boosted PI plus optimized background study, elvitegravir plus optimized background regimen was this study. Other clinical trials. No OT and AT data could be extracted for This time-weighted endpoint has not been further validated in other clinical trials. No OT and AT data could be extracted for this study.

Clinical outcome in treatment-experienced patients with virological failure

Data from three studies on ART-experienced patients with virological failure could be incorporated in the meta-analysis. Overall, a statistical significant OR in favour of INI use in this population was observed in the mITT meta-analysis (OR 0.27; 95% CI 0.11–0.66) (Figure 3B). The meta-analyses using OT data (OR 0.28, 95% CI 0.20–0.38) and AT data (OR 0.16, 95% CI 0.04–0.61) included two studies and confirmed this result (Figure S1B). The higher I² (mITT: 83.7%) and the Funnel plot (Figure S2B) point to a difference in study outcome, most likely influenced by differences in trial design and analyses.

Comparison of INI versus placebo both in combination with optimized background. In the BENCHMRK 1 and 2 trials comparing raltegravir (n = 459) to placebo (n = 237) in patients experiencing therapy failure, superior and sustained viral suppression was observed up to 96 weeks (mITT, 24 weeks: 62% versus 33% virological suppression, p<0.001) [2,35]. The majority of virus isolates of the raltegravir failure patients harbored integrase resistance mutations, most of which were already detected by 24 weeks of therapy. In the Protocol 005 study, the efficacy of several raltegravir dosages (200 mg, 400 mg or 600 mg bd) (n = 134) with optimized background versus placebo (n = 45) were evaluated in highly experienced patients with HIV RNA >5000 copies/ml [36,37]. At 24 weeks, 62.0% in all raltegravir treated groups versus 11.3% in the placebo group reached an undetectable viral load (mITT). Integrase mutations were observed in 35/38 INI treated patients failing therapy.

Comparison of INI versus PI both in combination with optimized background. In the GS-183-105 dose ranging study, elvitegravir plus optimized background regimen was compared with ritonavir boosted PI plus optimized background regimen (n = 63) in predominantly high PI experienced patients [38]. In the 50 mg qw arm (n = 75) elvitegravir was non-inferior while in the 125 mg arm (n = 73) elvitegravir was superior at reaching successful virological outcomes after 24 weeks (mITT time-weighted average change in log10 HIV-1 RNA (DAVG) treatment difference: −0.42, 95% CI −0.77 to −0.06, p = 0.021). This time-weighted endpoint has not been further validated in other clinical trials. No OT and AT data could be extracted for this study.

A subset of additional trials were reviewed but could not be included in the meta-analysis for various reasons. Three uncontrolled trials evaluated raltegravir in treatment-experienced patients in combination with other relatively new compounds. The first study is an open-label study describing the use of raltegravir with etravirine (400 mg bid) and an optimized background in patients experiencing treatment failure with darunavir (n = 20) [39]. 65% of participating patients obtained viral suppression at week 24 (mITT). The second study is ANRS 139 TRIO, which combined raltegravir and etravirine with ritonavir boosted darunavir (n = 103) in highly treatment-experienced patients experiencing virological failure. In this landmark study, the combination of three new compounds resulted in - at that time - fascinating high virological suppression rates (mITT: 86% at 48 weeks) among treatment-experienced patients and these results persisted up to 96 weeks [3,40]. Lastly, raltegravir in combination with etravirine and maraviroc (n = 28) was tested in an uncontrolled study among patients experiencing therapy failure. This approach resulted in high levels of virological suppression (mITT: % of patients HIV RNA <50 copies/ml: 92% at 48 weeks) and no virological failure [41].

Functional mono-therapy with raltegravir in triple-resistant patients (n = 67) was evaluated in one observational trial and showed high efficacy at 48 weeks (mITT: 64% of patients with HIV RNA <50 copies/ml) [42]. Raltegravir resistance was observed in all patients experiencing virological failure.

The GS-183-0145 study compared once-daily elvitegravir versus twice-daily raltegravir in combination with a fully active ritonavir boosted PI and a second agent in patients with virological failure [43]. This study could not be included in the meta-analysis because of comparison of two INI. Etravirine was non-inferior to raltegravir regarding virological response at 48 weeks (mITT). In case of failure, HIV-1 integrase resistance patterns by both drugs were comparable, indicating a similar genetic barrier and cross-resistance between both drugs [44].

The VIKING trials evaluating dolutegravir in raltegravir treatment-experienced patients could not be included in the meta-analysis due to their uncontrolled design [45–47]. In VIKING I dolutegravir 50 mg once daily (n = 27) and in VIKING II dolutegravir 50 mg twice daily (n = 24) were applied as functional mono-therapy for 10 days, followed by a subsequent replacement of the failing regimen by an optimized backbone. Use of dolutegravir in these cohorts resulted in a very high level of virological suppression at day 11 (mITT HIV RNA <50 copies/ml: 78% respectively 96%). Persistent viral suppression was observed in 41% respectively 52% of these highly experienced patients at week 24. On 15 paired viral isolates from day 1 and day 11 of VIKING II, 3/15 patients harboured additional raltegravir associated mutations. It could not be distinguished whether those mutations had been selected during initial raltegravir treatment or de novo during subsequent dolutegravir use [47].

Clinical outcome in treatment-experienced patients with suppressed viral load

Three studies on ART-experienced patients switching to INI while virologically suppressed were included in the meta-analysis: the analysis based on mITT data indicated a non-significant unfavourable OR when an antiretroviral drug was switched to an INI (OR 1.43; 95% CI 0.89–2.31) (Figure 3C). The meta-analysis based on AT data (OR 1.73, 95% CI 1.01–2.97) demonstrates inferiority after such switch (Figure S1C).

Comparison of INI versus PI both in combination with dual NRTI. In the SWITCHMRK 1 and 2 studies (n = 347 both arms), a switch from ritonavir boosted lopinavir towards
raltegravir-based ART was evaluated compared to continuation of the lopinavir-based therapy [40]. Baseline genotyping was not performed as patients had an undetectable viral load at screening. Archived resistance data were not taken into account. The studies were terminated prematurely because non-inferiority of raltegravir to ritonavir boosted lopinavir was not established at week 24 (mITT: treatment difference $-6.2\%$, $95\%$ CI $-11.2$ to $-1.3$). The lower success rate in the raltegravir arm was most likely due to inclusion of patients with a history of therapy failure and pre-existing resistance against the NRTI backbone. Patients without previous virological failure had similar virological response rates at week 24 in both arms. The majority of the assessable patients who rebounded on raltegravir-based therapy harbored raltegravir-resistant virus.

In SPIRAL, a second open-label trial, a switch of ritonavir boosted PI towards raltegravir ($n = 139$) versus continuation of the ritonavir boosted PI ($n = 134$) was evaluated in patients with well-documented treatment history and long-term virological suppression [49]. In the mITT analysis at week 32, the switch from any ritonavir boosted PI to raltegravir in patients with undetectable viral load resulted in comparable high rates of virological suppression. Low-level raltegravir resistance was observed in only one patient.

Comparison of INI versus enfuvirtide both with background regimen. In the EASIER-ANRS 138 trial two switch strategies were compared: one group switched immediately to raltegravir ($n = 85$), the second group continued the low genetic barrier drug enfuvirtide and switched only after 24 weeks ($n = 85$). When analyzing the mITT 24 week data, the switch from enfuvirtide to raltegravir in heavily pretreated patients with a viral load <100 copies/ml at inclusion, resulted in similar rates of viral suppression [30]. No raltegravir resistance was detected upon virological failure.

Four smaller observational single-armed studies – hence not included in the meta-analysis – evaluated the switch from enfuvirtide to raltegravir in patients with an undetectable viral load and reported high virological success rates at weeks 16 to 48 [51–54].

The ODIS trial evaluated two dosage schemes of raltegravir – not included in the meta-analysis – while switching from a protease inhibitor and found that the 600 mg once daily arm ($n = 149$) had higher rates of virological failure at 24 weeks compared to 400 mg twice-daily ($n = 73$). In patients with prior NRTI resistance, significant higher failure rates were seen in both arms [55]. RASTA (Raltegravir Simplification for Toxicity or Adverse events) compared switching to raltegravir 400 mg either with tenofovir/emtricitabine ($n = 21$) or with abacavir/lamivudine ($n = 19$) in patients on PI, NNRTI or NRTI-based therapy with suppressed viral load and found comparable virological suppression rates at 24 weeks. Only one patient experienced therapy failure after switching [56]. Anecdotal data from another small study ($n = 20$) which could not be included in the meta-analysis, showed high virological suppression up to 48 weeks in 96% of patients following regimen simplification towards a low genetic barrier regimen with raltegravir plus nevirapine ($n = 20$). Prior to the simplification, these patients were long-term suppressed on a regimen containing nevirapine most likely without a history of therapy failure [57].

Although several studies have been performed investigating the intensification effect of adding an INI to a successful regimen, the body of evidence from those studies is graded as insufficient [38–66]. The heterogeneous nature of the studies, using different outcome measures to assess clinical outcome, residual immune activation and viral replication, and the duration of intensification makes comparison and inclusion in a meta-analysis impossible.

Five other uncontrolled studies describing a switch to raltegravir and boosted or unboosted PI reported good results but the evidence graded as insufficient [67–71]. A varying percentage of participants with an undetectable viral load at start of those studies (63% to 100%), different outcome measures and study duration, all hampered uniform conclusions.

Pooled analysis of immunological efficacy, adverse events and emergence of drug resistance

When assessing the immunological response after start of INIs, the majority of the controlled studies with raltegravir, elvitegravir or dolutegravir indicate a similar median CD4 increase compared to other regimens. However, in therapy-naive patients, GS-236-0102 (48w), SINGLE (48w) and the long-term follow-up of STARTMRK (240w), all reported significantly higher CD4 increments compared to efavirenz-based therapies [14,19,23]. In the subgroup of treatment-experienced patients with virological failure, use of raltegravir resulted in significant better immunological outcome in BENCHMRK 1 and 2 compared to placebo (96w) [35]. ODIS reported similar significant results after switching to raltegravir from a boosted PI (24w) [35].

The INIs are generally well tolerated and rarely Grade 3 or 4 treatment-emerging adverse events are reported. Compared to efavirenz, discontinuation from INIs due to clinical adverse events is infrequent while compared to PIs, less severe and life-threatening laboratory abnormalities are observed. An overview of the major adverse events of all INIs can be found in Table 1.

In case of treatment failure in therapy-naive patients, few but high-level raltegravir and elvitegravir resistance was observed, which often conferred cross-resistance to these drugs. No resistance for dolutegravir in this patient population was detected. When combined with dual NRTI, the occurrence of raltegravir or elvitegravir resistance-associated mutations (RAM) was associated in 50% of cases with resistance to NRTI (Table S1).

Discussion

We performed a systematic review on all published clinical data concerning integrase inhibitors and subsequently meta-analyses on the virological outcome of those studies which included a controlled arm. Based on the meta-analyses, treatment with INIs in combination with dual NRTI showed to be more beneficial for treatment-naive patients compared to other currently used treatment strategies. Also in treatment-experienced patients with virological failure, use of INIs proved to be beneficial as well. However, in successfully treated patients with a history of therapy failure, switching a high genetic barrier drug towards an INI was not supported. More in depth, the following indications for use of integrase inhibitors can be summarized:

Initial therapy

The meta-analysis shows a significant OR in favor of INI combined with dual NRTI based on mITT and OT data, with a similar favorable trend when AT data are used. As both mITT and OT based meta-analyses show a similar significant OR, the clinical benefit of INIs is not only driven by improved tolerability, but also by higher antiviral efficacy. The non-significance of the AT-based meta-analysis can be due to small differences between OT and AT study populations, or might be influenced by the non-availability of AT data from a large dolutegravir trial.

In recent European and US treatment guidelines, raltegravir with a tenofovir/emtricitabine backbone is listed among the preferred regimens for antiretroviral-naive HIV infected individuals [4,5,72]. This is supported by the meta-analyses. Raltegravir
showed comparable high virological efficacy compared to efavirenz as first line antiretroviral regimen, but was found to be superior driven by its good toxicity profile and tolerability [17,18]. Besides its good tolerability, raltegravir has a limited risk for drug-drug interactions [73,74]. Disadvantages of raltegravir are the non-availability of a single tablet regimen and the twice-daily dosing schedule, as supported by the QDMRK study [23]. Raltegravir showed a low genetic barrier to drug resistance upon failure. The emergence of raltegravir resistance was infrequent, but often of high-level (at least two INI RAMs) and transferring cross-resistance to elvitegravir, confirming resistance profiles observed in earlier vitro studies [75].

More recently developed INIs like elvitegravir and dolutegravir hold promise as part of a single tablet regimen (STR) in first-line therapy. Boosted elvitegravir as part of a STR revealed promising results in two large trials, but caution is needed because of increased INI and NRTI resistance. A similar low genetic barrier to drug resistance upon failure was seen for elvitegravir. Raltegravir and elvitegravir based regimens showed comparable or superior immunological response compared to other regimens. Dolutegravir combined with abacavir/lamivudine has been the first combination reported to be virologically and immunologically superior compared to an efavirenz-based regimen. No drug resistance was detected suggesting a high genetic barrier to resistance development.

In this patient population, novel treatment strategies have been explored, such as the combination of INI with a PI, sparing the NRTIs. Individual studies are underpowered or failed to show superiority. Also the mITT, OT and AT-based meta-analysis failed to show significant odds ratios in favor of these nucleoside-sparing regimens. For stronger conclusions, more data are needed. Currently a large trial evaluating this concept (NEAT-001, tenofovir/emtricitabine/boosted darunavir versus raltegravir/boosted darunavir) is underway.

### Virological failure

The meta-analyses demonstrate convincing evidence for a treatment change towards a regimen containing raltegravir or elvitegravir compared to placebo and PI in PI pre-treated individuals with virological failure, based on mITT as well as OT and AT data. For dolutegravir, no randomized trials were available to include in the meta-analysis. Cross-resistance observed in these studies suggests no additional value for sequential use of raltegravir and elvitegravir. In contrast, dolutegravir has limited cross-resistance to other INIs based on a recent report, which could infer a potential role for this drug in INI-experienced patients depending on the resistance profile [45–47,66,77]. A timely switch or even interruption of raltegravir or elvitegravir may prevent accumulation of resistance and should be considered in order to maximize the potential effect of dolutegravir [78]. Similar or superior immunological response was observed for raltegravir and elvitegravir based regimens compared to other regimens.

### Regimen simplification

Switching from enfuvirtide to raltegravir resulted in high levels of durable suppression in several uncontrolled trials [51–54] indicating that substitution of a low genetic barrier component of combination antiretroviral therapy by raltegravir in patients with documented or suspected drug resistance can be safely performed [50]. In contrast, the switch from a high genetic barrier PI towards raltegravir in a similar population resulted in an unfavorable OR in the OT-based meta-analysis, and thus higher levels of therapy failure in the raltegravir arm. When adding the effect of adherence and tolerability (mITT), the unfavorable effect was less evident. Two major studies revealed conflicting results possibly influenced by duration of suppression and documentation of treatment history [48,49]. The results indicate that when switching virologically suppressed patients, individual patient management is needed to assess history of treatment failure, available resistance profiles and duration of the current suppressive regimens in order to perform a safe switch.

### Limitations of the systematic review and meta-analysis

One of the limitations of this systematic review and meta-analysis is potential variations in efficacy between the individual INIs compared in similar settings, inherent to the study methodology. Furthermore, the virological outcome data were obtained following different protocols. However, direct comparison of these methodologies has not revealed major differences in outcome [79–81]. The SINGLE trial could not be incorporated in the AT meta-analysis for therapy-naive patients, since the number of patients failing combination antiretroviral therapy during the study were not reported so far. In reviewing the current literature on the clinical use of INIs, it becomes obvious that certain clinical questions cannot be answered because of insufficient evidence due to the lack of controlled studies. One of these gaps concerns effect of treatment intensification. Another gap concerns use of INI during pregnancy, since good tolerability and rapid decline of HIV RNA in the plasma suggests a place for integrase inhibitors in this setting [82]. However, there is no evidence from large trials on efficacy and teratogenicity. Similarly, insufficient data are available to include raltegravir in standard post exposure prophylaxis regimens. With the anticipated arrival of studies with new available INIs these gaps could be closed. Finally, the review was restricted to English-language reports.

### Conclusion

The meta-analyses positioned INI as a preferred drug in the setting of treatment-naive and as beneficial addition in treatment-experienced patients with virological failure, based on virological efficacy. Careful use of INI when replacing a high genetic barrier PI is warranted. The perspectives of new single tablet regimens containing elvitegravir or dolutegravir taken in the absence of food restrictions hold promise for broad use in first line regimens. In general, the addition of the integrase inhibitor class to our armamentarium has strengthened cART regimens, and further rational use can preserve future therapeutic options.

### Supporting Information

#### Figure S1 Forest Plots of OT/AT meta-analyses.

**Panel A:** Forest plot showing the meta-analysis of OT and AT data extracted from studies with therapy-naive patients. **Panel B:** Forest plot showing the meta-analysis of OT and AT data extracted from studies with ART-experienced patients in case of virological failure. **Panel C:** Forest plot showing the meta-analysis of OT and AT data extracted from studies with ART-experienced patients switching with suppressed viral load. OT = on-treatment; AT = as-treated; ART = antiretroviral treatment; INI = integrase inhibitor; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; T20 = enfuvirtide; OR = odds ratio. (TIF)

#### Figure S2 Funnel Plots of the mITT meta-analyses.

A funnel plot is a scatterplot of treatment effect against a measure of funnel plot is a scatterplot of treatment effect against a measure of
besides the number of patients experiencing treatment failure in population size in the INI-arm and control arm are reported, clinical settings, data were extracted on emergence of drug studies on INI use.

**References**

1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Accessible at http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf. Accessed 10/10/2012 2012/10/16. Geneva.

2. Steingold RF, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 359–364.

3. Yarzapanah Y, Fagard C, Descamps D, Taburet AM, Colín C, et al. (2009) High rate of virologic suppression with raltegravir plus etravirine and dolutegravir in ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: the results of the ANRS 139 TRIO trial. Clin Infect Dis 49: 1440–1449.

4. Department of Health and Human Services. DHHS Guidelines for the Use of Antiretroviral Drugs in HIV-1-Infected Adults and Adolescents - October 14, 2011. Accessible at http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7. Accessed 2012/10/16.

5. European AIDS Clinical Society. EACS European Guidelines for treatment of HIV-infected adults in Europe. Accessible at http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=39&Itemid=41. Accessed 2012/10/16.

6. Relevo R, Balshem H (2011) Finding evidence for comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of clinical epidemiology 64: 1168–1177.

7. Moller D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 6: e1000097.

8. Owens DK, Lohr KN, Atkinson D, Treadwell JR, Reston JT, et al. (2010) AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. Journal of clinical epidemiology 63: 513–523.

9. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22: 719–746.

10. Viera AJ (2005) Odds ratios and ratio risks: what’s the difference and why do they matter? Southern medical journal 101: 730–734.

11. US Department of Health and Human Services Food and Drug Administration. CDER (2002) Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf. Accessed 2012/08/23.

12. Wittkop L, Smith G, Fox Z, Sabin C, Richert L, et al. (2010) Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical trials (London, England) 7: 19–35.

13. Kozal MJ, Lupio S, DeJesus S, Molina JM, McDonald C, et al. (2012) A nucleoside- and nucleotide-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV clinical trials 13: 119–130.

14. Walmsley S, Antraa A, Clumeck N, Duiculescu D, Eberhard A, et al. (2012) Dolutegravir (TDF; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (JGG14467). Abstract H-556b. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco.

15. Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, et al. (2010) Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 55: 39–48.

16. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796–806.

17. Rockstroh J, Lazzarin A, Zhao J, Rodgers A, DinNuhle M, et al. (2011) Long-term Efficacy of Raltegravir (RAL) or Efavirenz (EFV) Combined with Tenofovir (TDF) and Emtricitabine (FTC) in Treatment-naive HIV-1 Patients: WK-192 Subgroup Analyses from STARTMRRK. Study Abstract No: PEF9.17. 13th European AIDS Clinical Society Conference. Belgrade.

18. Rockstroh JK, Lennox JL, DeJesus E, Saag MS, Lazzarin A, et al. (2011) Long-term treatment with raltegravir or efavirenz combined with tenofovir/ emtricitabine for treatment-naive human immunodeficiency virus-infected patients: 156-week results from STARTMRRK. Clin Infect Dis 53: 876–876.

19. Rockstroh J, DeJesus E, Saag M, Yazdanpanah Y, Lennox J, et al. (2012) Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-1-infected patients: final 5-year double-blind results from STARTMRRK. Abstract LBPE19. XIX International AIDS Conference. Washington DC.

20. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2009) Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Journal of acquired immune deficiency syndromes (1999) 46: 125–133.

21. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Journal of acquired immune deficiency syndromes (1999) 46: 125–133.

22. Gotuzzo E, Nguyen BY, Markowitz M, Mendo F, Ratanasuwan W, et al. (2011) Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naive HIV-infected patients; final analysis of protocol 004. Abstract no. EPDPB0102 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome.

23. Eron JJ Jr, Rockstroh JK, Reyes J, Andrade-Villanueva J, Ramalho-Madruga JV, et al. (2011) Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. The Lancet infectious diseases 11: 907–915.

24. Young B, Yang T, DeJesus E, Hawkins T, St Clair M, et al. (2011) 96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naive, HIV-1-infected patients: the SHIELD trial. HIV Clin Trials 12: 228–235.

25. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, et al. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379: 2439–2448.

26. Cohen C, Elion R, Ruanne P, Shambhavi D, DeJesus E, et al. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir. PLOS ONE | www.plosone.org 14 January 2013 | Volume 8 | Issue 1 | e52562
tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25: F7-12.

27. Rockstroh J, Felizarda F, Mąggiolo F, Pudlo F, Stellbrink H, et al. (2010) Once-daily S/GSK1349572 combination therapy in antiretroviral-naive adults: Rapid and significant improvement in antiretroviral responses in SPRING-1 (ING112966). Abstract O50. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.

28. van Lunzen J, Maggiolo F, Arribas JR, Rakhatitsa A, Yeni P, et al. (2011) Once-daily dolutegravir (DTG; S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1 (ING112966). Abstract TUB031062. 11th IAS Conference on HIV Pathogenesis, treatment and prevention. Rome.

29. Raffi F, Rühe L, Stellbrink HJ, Hardy WD, Torti C, et al. (2012) Once-daily darunavir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING139086). Abstract TBLRB04. XIX International AIDS Conference. Washington DC.

30. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, et al. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379: 2429-2438.

31. Reiss P, Lalau A, Pirozzi S, Totaro E, Ghezzi P, et al. (2011) Efficacy of the nucleoside-monomer regimen stavudine plus lamivudine compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress 48, week 56. Results. HIV clinical trials 12: 255-267.

32. Boccardo R, Drechler H, Turner D, Moore T, Ghornley J, et al. (2011) RADAR study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Abstract no. MOPE214. 6th IAS Conference on HIV Pathogenesis, treatment and prevention. Rome.

33. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al. (2011) Efficacy and safety of raltegravir in treatment-experienced patients with triple-class experience. AIDS (London, England) 25: 27-35.

34. Molina JM, Lazzarin A, Rabinovich G, Szwarcberg J, Miller MD, et al. (2010) Raltegravir in treatment-experienced HIV-1-infected patients: the SPIRAL study. AIDS. London, England 24: 1967-1970.

35. Sallan S, Braun J, Delaforge L, Charreau I, Reynes J, et al. (2011) Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother. 66: 2099-2106.

36. Harris M, Larsen G, Montaner JS (2008) Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 22: 1224-1226.

37. Santos JR, Llibre JM, Ferrer E, Domingo P, Imsa A, et al. (2009) Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clin Trials 10: 432-438.

38. Talbot A, Macnab N, Thomas R, Marotte S, Therrien R, et al. (2009) Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort. J Acquir Immune Defy Syndr 51: 362-364.

39. Towner W, Klein D, Kerrigan HL, Follmabee S, Yu K, et al. (2009) Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide-based regimen: 24-week results of the CHEER study. J Acquir Immune Defy Syndr 51: 372-376.

40. Vispo E, Barreiro P, Maata I, Mena A, Blanco F, et al. (2010) Simplification from protease inhibitors to once or twice-daily raltegravir: the ODIS trial. HIV clinical trials 11: 197-204.

41. Di Giambenedetto S, Giachino M, Colafigli M, Bracciale E, L'attorre G, et al. (2011) Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients on PI, NRTI or NRTI-based therapy with optimal virologic control: 24 weeks results from a randomized pilot study. Abstract no. CDB536. 6th IAS Conference on HIV Pathogenesis, treatment and prevention. Rome.

42. Reliquet V, Chirouze C, Muret P, Peytavin G, Ferré V, et al. (2011) Raltegravir (RAR) and nevirapine (NVP) dual therapy maintains virologic suppression in HIV-infected HAART-treated patients: 48-week results of a pilot study. Abstract no. CDB536. 6th IAS Conference on HIV Pathogenesis, treatment and prevention. Rome.

43. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dysfunction are affected by rapid intensification of HAART-suppressed subjects. Nature medicine 16: 460-465.

44. Yabkova H, Kelly M, Purcell DF, French MA, Amin J, et al. (2011) Intensification of antiretroviral therapy with raltegravir or addition of lamivudine to HAART in infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. The Journal of infectious diseases 204: 1532-1540.

45. Cesar C, Patterson P, Vázquez ML, Zapio I, Saracco M, et al. (2011) Raltegravir intensification in HIV-infected patients with immune discordant response to HAART. Abstract no. MOPE166. 6th IAS Conference on HIV Pathogenesis, treatment and prevention. Rome.

46. Gandhi RT, Coober BW, Chan ES, Bosch RJ, Zheng L, et al. (2011) No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-infected Patients Receiving Antiretroviral Therapy. Journal of acquired immune deficiency syndromes (1999).

47. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. (2010) Effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS medicine 7.

48. Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, et al. (2010) Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defy Syndr 54: 389-395.

49. Lichtenstein K, Harbeck R, Nagabhushanam V, Hiserote M, Efaw B, et al. (2010) A pilot study to assess the immunological response when raltegravir is added to a virologically suppressed regimen. Abstract O51. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.

50. Margot NA, Nau MK, Wray C, Syrnicki J, Egypt J, et al. (2009) Activity and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor-based, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 12: 27-35.

51. Morlat P, Mardere M, Lazzarin A, Katlama C, et al. (2010) Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: Week 24 results of the VIKING study (ING112961). Abstract O51. Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom.
immunoactivation in subjects on suppressive therapy. The Journal of infectious diseases 204: 1936–1945.

67. Allavena C, Mounoury O, Rodallec A, Daily E, Joffelin T, et al. (2009) Raltegravir plus a boosted protease inhibitor: experience of a novel dual combination in HIV-infected antiretroviral-experienced patients. Abstract-No: PE.7.9/17. 12th European AIDS Clinical Society Conference Koln.

68. Cordery DV, Hesse K, Amin J, Cooper DA (2010) Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral-treatment-experienced HIV patients. Antivir Ther 15: 1035–1038.

69. Ripamonti D, Maggiolo F, Bombana E, Gregis G, Quinzan G, et al. (2009) Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral-experienced patients. Abstract no. MOPE667. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa.

70. Tsukada K, Nishijima T, Gatanaga H, Kanaya F, Kikuchi Y, et al. (2011) Efficacy of NRTI-sparing regimen of raltegravir plus boosted darunavir in NRTI intolerant patients. Abstract no. CDB353 6th IAS Conference on HIV pathogenesis, treatment and prevention. Rome.

71. Gardner EM, Melendez AG, Astiz M, Bray K (2012) Adherence and Preexisting Major Protease Inhibitor Resistance Mutations are Associated with Virologic Failure of a Dual-Class Antiretroviral Regimen with Inhibitors of HIV-1 Viral Protease and Integrase. Journal of the International Association of Physicians in AIDS Care Chicago, Ill 11: 34–39.

72. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardi G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321–333.

73. Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, et al. (2011) Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrobial agents and chemotherapy 55: 321–325.

74. Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, et al. (2010) Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 65: 320–326.

75. Goethals O, Clayton R, Van Ginneken M, Verreycken I, Wagenaar E, et al. (2008) Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 82: 10366–10374.

76. Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, et al. (2011) Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. The Journal of infectious diseases 204: 1811–1815.

77. Highlowe K, Wang R, Seki T, Kobayashi M, Underwood M (2011) Slow dissociation of Dolutegravir (S/GSK1349572) contributes to an improved resistance profile with integrase inhibitor-resistant mutants. Abstract O_02. 9th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. Paphos, Cyprus.

78. Clotet B, Katlama C, Soriano V, Lazzarin A, Richmond GJ, et al. (2011) HIV Integrase resistance and phenotypic susceptibility to Dolutegravir (DTG, S/GSK1349572) for subjects with virological failure on Raltegravir (RAL). Abstract O_03. 9th European Workshop on HIV & Hepatitis Treatment Strategies and Antiviral Drug Resistance. Paphos, Cyprus.

79. Qaqish R, van Wyk J, King MS (2010) A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs twice daily lopinavir/ritonavir (LPV/r) regimens. Journal of the International AIDS Society 2010 (Suppl 4):P58.

80. Smith F, Hammerstrom T, Soon G, Zhou S, Chen B, et al. (2011) A meta-analysis to assess the FDA DAVP’s TLOVR algorithm in HIV submissions. Drug Inf J 45: 291–300.

81. Zhang W, Pannucci M, Guo J, Hall D (2011) Comparison of TLOVR Algorithm Versus Snapshot Approach for HIV Studies. Abstract - #301734. 2011 Joint Statistical Meetings. Miami.

82. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States—September 14, 2011. Accessible at http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed 2012/10/16.

83. Fallon JP, Kiaras A, Correll TA, Qaqish RB, Woodward WC, et al. (2010) Safety and efficacy of lopinavir/ritonavir (LPV/r) in combination with raltegravir (RAL) in HIV-infected subjects: 24 week interim analysis. Abstract no. THPE8078. XVIII International AIDS Conference. Vienna.